Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma

Name: Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma
Published: 2019
License: Public Domain

First Affiliated Hospital of Fujian Medical University · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

immune-checkpoint-inhibitor pembrolizumab progression-free-survival radiomics treatment-response

metastatic renal cell carcinoma, 18f-fdg pet/ct, radiomics, multi-lesion radiomics, tyrosine kinase inhibitor, immune checkpoint inhibitor, treatment response, progression-free survival, axitinib, pembrolizumab, toripalimab, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma

Related documents